MIRM
Mirum Pharmaceuticals Inc

1,602
Mkt Cap
$3.5B
Volume
690,513.00
52W High
$78.54
52W Low
$36.88
PE Ratio
-79.03
MIRM Fundamentals
Price
$68.11
Prev Close
$67.72
Open
$67.08
50D MA
$72.95
Beta
0.76
Avg. Volume
578,376.83
EPS (Annual)
-$1.85
P/B
11.97
Rev/Employee
$1.05M
Loading...
Loading...
News
all
press releases
FY2027 Earnings Estimate for MIRM Issued By Leerink Partnrs
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Investment analysts at Leerink Partnrs raised their FY2027 earnings estimates for Mirum Pharmaceuticals in a research report issued to...
MarketBeat·20h ago
News Placeholder
More News
News Placeholder
Research Analysts Offer Predictions for MIRM FY2028 Earnings
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note...
MarketBeat·20h ago
News Placeholder
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs...
Business Wire·21h ago
News Placeholder
Mirum Pharmaceuticals (NASDAQ:MIRM) Posts Earnings Results, Beats Expectations By $0.15 EPS
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate...
MarketBeat·2d ago
News Placeholder
Citizens Jmp Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock
Citizens Jmp upped their target price on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company a "market outperform" rating in a research report on Wednesday...
MarketBeat·2d ago
News Placeholder
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Zacks·3d ago
News Placeholder
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +150.00% and +0.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2025 and provided a business update. Mirum is well positioned heading into 2026 with strong...
Business Wire·4d ago
News Placeholder
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...
Business Wire·5d ago
News Placeholder
Techne (TECH) Reports Next Week: What to Know Ahead of the Release
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·10d ago

Latest MIRM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.